A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer - Concepedia

Concepedia

Publication | Open Access

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

DOI Full Paper Access

20

Citations

22

References

2015

Year

Alex A. Adjei, Donald Richards, Anthony B. El-Khoueiry, Fadi Braiteh, Carlos H.R. Becerra, Joe Stephenson, Aram F. Hezel, Morris Sherman, Lawrence Garbo, Diane P. Leffingwell,

Clinical Cancer Research

Abstract

In this phase I study, refametinib plus sorafenib was well tolerated, with good oral absorption, near-dose proportionality, and target inhibition in a range of tumor types. Clin Cancer Res; 22(10); 2368-76. ©2015 AACR.

References

	Year	Citations

Page 1